Abstract:Purpose Sirtuin7 (SIRT7), as a member of the sirtuin and NAD + -dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein–protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling. Methods USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student’s t test (two-tailed unpaired) and χ 2 test. Results We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer. Conclusion Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.

USP13 regulates the replication stress response by deubiquitinating TopBP1

USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response

USP37 Regulates DNA Damage Response Through Stabilizing and Deubiquitinating BLM

USP39 Regulates DNA Damage Response and Chemo-Radiation Resistance by Deubiquitinating and Stabilizing CHK2.

HERC2-USP20 axis regulates DNA damage checkpoint through Claspin.

The Deubiquitinase Usp36 Regulates Dna Replication Stress And Confers Therapeutic Resistance Through Primpol Stabilization

USP51 Deubiquitylates H2AK13,15ub and Regulates DNA Damage Response.

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

USP52 Regulates DNA End Resection and Chemosensitivity Through Removing Inhibitory Ubiquitination from CtIP

USP49 participates in the DNA damage response by forming a positive feedback loop with p53

A Divergent Role of the SIRT1-TopBP1 Axis in Regulating Metabolic Checkpoint and DNA Damage Checkpoint.

USP13: Multiple Functions and Target Inhibition

The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

USP10 Regulates p53 Localization and Stability by Deubiquitinating p53

USP50 suppresses alternative RecQ helicase use and deleterious DNA2 activity during replication

The dimeric deubiquitinase USP28 integrates 53BP1 and MYC functions to limit DNA damage

The deubiquitinase USP38 promotes NHEJ repair through regulation of HDAC1 activity and regulates cancer cell response to genotoxic insults.

A Selective USP1–UAF1 Inhibitor Links Deubiquitination to DNA Damage Responses

USP37 prevents premature disassembly of stressed replisomes by TRAIP

Data from The Deubiquitinase USP38 Promotes NHEJ Repair through Regulation of HDAC1 Activity and Regulates Cancer Cell Response to Genotoxic Insults

USP7 Negatively Controls Global DNA Methylation by Attenuating Ubiquitinated Histone-Dependent DNMT1 Recruitment